Paradigm Biopharmaceuticals Limited (PAR.AX)
Develops injectable drugs to treat osteoarthritis, viral infections, and heart disease.
0.17+0.00%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-52.2%
The outlook
PAR.AX is trading near its 52-week lows, well below both its 50- and 200-day moving averages, signaling a weak near-term trend. Analyst coverage shows a notably bullish average price target sitting around 564% above the current price, though this disconnect with current price action reflects high uncertainty. Overall sentiment leans bearish.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range9% of the way from its 52-week low to high
Price targetAvg target +564% vs current price
Analyst price target
~12-month · 2 analysts1.10average target+563.6% vs now
Now 0.17
Low 0.45High 1.74
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$98.0M
52-wk high
0.47
52-wk low
0.14
50-day avg
0.17
200-day avg
0.27
Trailing P/E
—